Lineage Cell Therapeutics, Inc. (LCTX)
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $14.6M
- Net income
- -$63.5M
- Total assets
- $112.6M
- Market cap
- $296.7M
- Operating margin
- -251.6%
- Net margin
- -435.3%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $14.6M
- Operating expenses
- $51.2M
- Operating income
- -$36.6M
- Income tax
- -$5.3M
- Net income
- -$63.4M
- EPS (basic)
- $-0.28
- EPS (diluted)
- $-0.28
Balance sheet
- Total assets
- $112.6M
- Current assets
- $59.2M
- Total liabilities
- $69.2M
- Current liabilities
- $11.4M
- Shareholders’ equity
- $43.3M
Cash flow
- Operating cash flow
- -$18.9M
- Investing cash flow
- -$13.5M
- Financing cash flow
- $26.9M
- Net cash flow
- -$5.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $296.7M
- EPS (diluted)
- $-0.28
- Shares outstanding
- 288.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Mar 5, 1992
Lineage Cell Therapeutics, Inc. (LCTX) Stock Price
- Reported a net loss of $63.5M in FY2025.
- Revenue grew 235% from FY2021 to FY2025.
- Trading 47% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Lineage Cell Therapeutics, Inc..
Write a review
News about Lineage Cell Therapeutics, Inc.
News & sentiment via Polygon.io
Lineage Cell Therapeutics, Inc.: frequently asked questions
Is Lineage Cell Therapeutics, Inc. an American company?
Lineage Cell Therapeutics, Inc. is a US-based company headquartered in Carlsbad, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Lineage Cell Therapeutics, Inc. headquartered?
Lineage Cell Therapeutics, Inc. is headquartered in Carlsbad, California, United States.
Is Lineage Cell Therapeutics, Inc. publicly traded?
Yes — Lineage Cell Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol LCTX on the NYSE.
What does Lineage Cell Therapeutics, Inc. do?
Lineage Cell Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
